BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli Sells 1,000 Shares

Key Points

• Maricel Apuli, the CAO of BridgeBio Pharma, sold 1,000 shares at an average price of $45.44, decreasing her ownership in the company to 141,859 shares.
• The company reported a **significant revenue increase** of 4999.9% year-over-year with quarterly earnings showing an EPS of ($0.95), missing the consensus estimate by ($0.12).
• Analysts have given BridgeBio Pharma a **consensus rating** of "Moderate Buy" with an average price target of **$61.35**, following revised price targets from multiple firms.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 1,000 shares of the company's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $45.44, for a total transaction of $45,440.00. Following the sale, the chief accounting officer owned 141,859 shares in the company, valued at $6,446,072.96. This represents a 0.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO traded up $1.66 during trading hours on Monday, hitting $48.24. The company's stock had a trading volume of 2,335,431 shares, compared to its average volume of 3,059,899. The firm's fifty day moving average price is $43.66 and its 200 day moving average price is $37.49. BridgeBio Pharma, Inc. has a 52 week low of $21.72 and a 52 week high of $49.77. The company has a market capitalization of $9.22 billion, a price-to-earnings ratio of -11.79 and a beta of 1.23.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $110.57 million during the quarter, compared to analysts' expectations of $98.46 million. During the same period in the previous year, the company posted ($0.39) EPS. The company's revenue was up 4999.9% on a year-over-year basis. On average, equities research analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Institutional Trading of BridgeBio Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc raised its position in BridgeBio Pharma by 2.8% during the fourth quarter. Legal & General Group Plc now owns 134,038 shares of the company's stock worth $3,678,000 after acquiring an additional 3,706 shares during the period. Raymond James Financial Inc. purchased a new position in BridgeBio Pharma during the fourth quarter worth about $456,000. Sterling Capital Management LLC grew its position in BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after acquiring an additional 1,514 shares during the period. Summit Investment Advisors Inc. increased its position in shares of BridgeBio Pharma by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company's stock worth $404,000 after purchasing an additional 466 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of BridgeBio Pharma in the 4th quarter worth approximately $366,000. Institutional investors and hedge funds own 99.85% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Raymond James Financial began coverage on BridgeBio Pharma in a research note on Wednesday, July 30th. They set an "outperform" rating and a $56.00 price objective on the stock. Wells Fargo & Company raised their price target on BridgeBio Pharma from $67.00 to $76.00 and gave the stock an "overweight" rating in a research report on Monday, June 30th. Citigroup boosted their price objective on shares of BridgeBio Pharma from $58.00 to $67.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Oppenheimer raised their target price on shares of BridgeBio Pharma from $60.00 to $61.00 and gave the stock an "outperform" rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their price target on shares of BridgeBio Pharma from $50.00 to $54.00 and gave the stock a "buy" rating in a research note on Wednesday, June 25th. One research analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $61.35.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.